559 related articles for article (PubMed ID: 22004085)
1. Inhibition of Ras for cancer treatment: the search continues.
Baines AT; Xu D; Der CJ
Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
[TBL] [Abstract][Full Text] [Related]
2. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
3. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
4. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
6. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ras oncogene: a novel approach to antineoplastic therapy.
Scharovsky OG; Rozados VR; Gervasoni SI; Matar P
J Biomed Sci; 2000; 7(4):292-8. PubMed ID: 10895051
[TBL] [Abstract][Full Text] [Related]
8. Targeting RAS in pediatric cancer: is it becoming a reality?
Vaseva AV; Yohe ME
Curr Opin Pediatr; 2020 Feb; 32(1):48-56. PubMed ID: 31815779
[TBL] [Abstract][Full Text] [Related]
9. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
10. Ras family signaling: therapeutic targeting.
Cox AD; Der CJ
Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
[TBL] [Abstract][Full Text] [Related]
11. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C; Burkhart DL; Haigis KM
Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
[TBL] [Abstract][Full Text] [Related]
12. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
15. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward J
Clin Cancer Res; 2015 Apr; 21(8):1802-9. PubMed ID: 25878361
[TBL] [Abstract][Full Text] [Related]
16. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
17. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
18. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
19. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
20. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]